Surgical oncology is not a dying field. It is changing significantly, but demand for surgical oncologists continues to grow, fellowship positions fill completely, and the rising global cancer burden virtually guarantees the specialty’s relevance for decades. The concern is understandable: newer drug therapies, organ-preservation protocols, and shifting reimbursement trends can make it look like surgeons are being squeezed out of cancer care. The reality is more nuanced.
Fellowship Demand Remains Strong
In the 2025 fellowship match cycle, all 77 certified surgical oncology positions filled, a 100% fill rate. There were 111 applicants competing for those spots, meaning 34 qualified candidates went unmatched. A dying field doesn’t turn away a third of its applicants. The specialty remains competitive to enter, which reflects both institutional investment in training programs and strong interest from general surgery residents who see a viable career ahead.
Cancer Cases Are Rising, Not Falling
The single biggest driver of surgical oncology’s future is demographics. The global population is aging rapidly, and cancer is overwhelmingly a disease of older adults. New cancer cases among people over 60 are projected to rise from 11.3 million to 19.8 million by 2040, a 75% increase. Cancer deaths in this group are expected to climb by nearly 83% over the same period. Even if a smaller percentage of those patients ultimately need surgery, the raw numbers translate into growing demand for surgical evaluation, staging, and operative intervention.
The U.S. Bureau of Labor Statistics projects 4% employment growth for surgeons through 2034, which is slightly above the 3% average for all occupations. That’s modest, but it doesn’t signal contraction. For context, dermatology and psychiatry lead physician growth projections at 6%, while general internal medicine and family medicine sit at 3%. Surgical oncology isn’t booming relative to other specialties, but it’s keeping pace.
How Drug Therapies Are Reshaping Surgery
The biggest shift in surgical oncology isn’t the elimination of surgery. It’s the transformation of when and how surgery happens. Pre-operative (neoadjuvant) chemotherapy and immunotherapy now shrink tumors before the surgeon ever picks up a scalpel. In breast cancer, for example, neoadjuvant therapy reduces the median tumor size from 14 mm to 7 mm and can cut the total volume of tissue removed nearly in half for certain tumor types. That means less radical operations, better cosmetic outcomes, and faster recovery for patients.
This changes what surgical oncologists do on a daily basis, but it doesn’t make them unnecessary. Someone still needs to perform the resection, interpret pathological margins, and manage complications. Neoadjuvant therapy also introduces new surgical challenges: identifying residual disease in a treated tumor bed is technically harder, and positive margin rates can actually increase (14% after neoadjuvant therapy versus about 9% without it in one breast cancer study). The operations are different, not gone.
Organ Preservation and “Watch and Wait”
Rectal cancer offers the clearest example of a cancer type where surgery is sometimes being avoided entirely. Patients who achieve a complete clinical response after chemotherapy and radiation can enter a “watch and wait” protocol, skipping the major operation (total mesorectal excision) that traditionally followed. This approach has gained traction because the surgery itself carries significant complications and long-term effects on bowel, bladder, and sexual function.
This is a genuine reduction in operative volume for one cancer type. But it also illustrates why surgical oncologists remain central to the process. They are the ones selecting patients for organ preservation, performing the staging assessments, monitoring for recurrence, and stepping in with salvage surgery when watch-and-wait fails. The role shifts from operator to decision-maker, but the expertise stays essential. Surgical oncologists who published the landmark review of this strategy explicitly framed it as information “for colorectal surgeons and surgical oncologists interested in this treatment alternative,” not as a replacement for the specialty.
New Procedures Are Expanding the Field
While some traditional operations are shrinking in scope, entirely new procedures have emerged that only surgical oncologists perform. Cytoreductive surgery combined with heated intraperitoneal chemotherapy (HIPEC) is now performed routinely worldwide for cancers that have spread to the abdominal lining. Mortality rates at high-volume centers have dropped to 0-1%, down from much higher historical rates, making it a viable option for more patients. Minimally invasive versions of HIPEC are also gaining ground, further expanding the patient population that can benefit.
A newer technique called pressurized intraperitoneal aerosol chemotherapy (PIPAC), first proposed in 2011, uses the pressure created during laparoscopic surgery to deliver aerosolized chemotherapy directly to tumor cells. It can be repeated easily and has shown favorable safety profiles. These are procedures that require a surgeon with oncologic training, and they represent growth areas that didn’t exist a generation ago.
Robotic surgery has also reshaped the operative landscape. A study of over 2.2 million cancer patients found that 59% of minimally invasive solid-organ cancer surgeries in the U.S. are now performed robotically. Robotic approaches have significantly lower rates of conversion to open surgery (3.7% versus 8.8% for traditional laparoscopic techniques). Mastering these platforms is now a core part of surgical oncology training and practice.
The Shift Toward Team-Based Decisions
One of the more significant changes is that surgical oncologists no longer make treatment decisions alone. Multidisciplinary tumor boards, where surgeons, medical oncologists, radiation oncologists, radiologists, and pathologists review cases together, now guide treatment planning for most cancer patients. A study evaluating tumor board outcomes found that the final multidisciplinary recommendation matched the surgeon’s initial plan only about 37% of the time. In 38% of cases the board added to or altered the surgical plan, and in 25% of cases the board replaced the surgeon’s recommendation entirely.
This can feel threatening if you view the surgeon as the captain of the ship. But it reflects the growing complexity of cancer care, not the irrelevance of surgical input. The surgeon’s perspective is one of several voices in the room, and their assessment of what’s technically resectable often determines whether a patient is treated with curative or palliative intent. The role has evolved from autonomous decision-maker to collaborative expert, which is a cultural shift more than a professional decline.
The Reimbursement Problem Is Real
If there’s a legitimate economic concern, it’s about money. Over the past 23 years, every surgical specialty has seen inflation-adjusted Medicare reimbursement decline. Vascular surgery took the worst hit at 43%, but no specialty was spared, with nearly two-thirds of all surgical billing codes losing value after adjusting for inflation. Meanwhile, drug-based cancer treatments generate substantial revenue for medical oncology practices.
This reimbursement squeeze is a real pressure on surgical practice, and it affects career satisfaction, practice sustainability, and the financial calculus for trainees carrying significant debt. But it’s a problem shared across all of surgery, not unique to surgical oncology, and it hasn’t translated into fewer positions or lower match rates.
What’s Actually Happening to the Field
Surgical oncology is contracting in some narrow areas (fewer radical operations, more organ preservation) while expanding in others (robotic platforms, HIPEC/PIPAC, complex multivisceral resections, and the management of patients receiving neoadjuvant therapy). The surgeon’s day looks different than it did 20 years ago: more time in tumor boards, more minimally invasive procedures, more collaboration with medical and radiation oncologists, and fewer cases where the surgeon is the sole architect of the treatment plan.
For someone considering the field as a career, the question isn’t whether surgical oncology will exist in 2040. With 19.8 million new cancer cases expected annually among older adults alone, it will. The better question is whether you’re comfortable with what the field is becoming: technically demanding, highly collaborative, and increasingly reliant on understanding the biology of cancer rather than just the anatomy of resection.